The long-term goal of this new project is to elucidate the mechanism of pDC/IFN-induced immune suppression during persistent HIV infection, and develop novel strategy of pDC/IFN-I blockade to control HIV reservoirs. I postulate that the HIV-activated pDC/IFN-I axis depletes and impairs anti-HIV T cells to maintain HIV- 1 persistence. Thus transient pDC/IFN-I interruption will provide a novel approach of immune recovery in cART- treated HIV-1 patients and improved control of viral rebound after cART cessation. In addition, restoring human immunity by transient pDC/IFN-I interruption prior to therapeutic vaccination will also enhance vaccine efficacy to control HIV-1 reservoirs. This project is proposed based on several recent findings from the multiple PIs? labs in HIV-infected humanized mice and in SIV-infected NHP. (i) Although pDC/IFN-I is critical to suppress acute HIV-1 replication and to prime anti-HIV T cells, depletion of pDC during persistent HIV-1 infection reverses HIV-1 diseases in humanized mice, even in the presence of elevated HIV-1 replication, and rescued anti-HIV T cells. (ii) blocking IFNAR with an mAb also reversed HIV diseases in HIV infected humanized mice, ?phenocopying? pDC depletion. (iii) In HIV-infected hu-mice under cART, IFNAR blockade or pDC depletion reversed inflammation, rescued human T cells and reduced HIV+ reservoir cells, via CD8-dependent mechanism. (iv) CD40-targeting vaccines induced T cell responses and reduced HIV reservoirs in humanized mice and SIV reservoirs in NHP. We hypothesize that IFN-I from persistently activated pDC contribute to HIV-induced aberrant inflammation, impaired immunity and HIV-1 persistence. The project will elucidate mechanisms of pDC/IFN-induced immune suppression (Aim 1) and functionally define the role of pDC/IFN-I in SIV persistence during cART (Aim 2). We will also explore the idea of blocking pDC/IFNAR prior to therapeutic vaccination under cART to control or cure HIV-1 or SIV reservoirs in humanized mice or in NHP models (Aim 3). Findings from the proposed aims will not only elucidate novel mechanisms of pDC/IFN-I in impairing host immunity, the IFNAR blocking bAb and pDC depleting dAb will also be developed into novel therapeutics to 1) resolve aberrant inflammation and recover immune activity in HIV- 1 patients under cART and 2) enhance therapeutic vaccination to achieve control of HIV rebound after cART interruption (functional cure).

Public Health Relevance

This project is to study the HIV-pDC/IFN axis in immune suppression during persistent HIV infection, define the role of pDC/IFN-I in HIV/SIV reservoir persistence during cART and develop novel therapeutic approach to controlling the HIV reservoir. Findings from the proposed project will not only elucidate novel mechanisms of pDC/IFN-I in impairing host immunity, the IFNAR blocking and pDC depleting antibodies will also be developed into novel therapeutics for treating inflammatory diseases in HIV-1 patients and for enhancing HIV-1 therapeutic vaccination to achieve HIV cure.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Mcdonald, David Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Medicine
Chapel Hill
United States
Zip Code